Table 2.
Selected studies of postoperative hypofractionated stereotactic radiotherapy (HSRT) to surgical bed
| References | Pts (No) | Date | Interval between surgery/SRS | SRS modality | Median dose (Gy)/fractions | PTV (cc) | CTV/PTV margins (mm) | Median follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| Minniti et al. [24] | 101 | 2005–2012 | 3 w | LINAC | 27/3 fr | 29.5 (18.5–52.7) | 2 mm | 16 |
| Ahmed et al. [25] | 65 | 2009–2013 | 5 w (1–15) | LINAC | 25–30/5 fr | 16.88 (4.9–128.4) | 1–2 mm | 8.5 |
| Keller et al. [26] | 187 | 2008–2015 | 6.5 w | LINAC | 33/3 fr | 14.15 (0.8–65.8) | 2 mm | 15 |
| Minniti et al., [27] | 60 | 2008–2015 | 3 w | LINAC | 27/3 fr | 20.6 (6.1–66.8) | CTV, 1 mm; PTV, 1 mm | 13 |
| Zhong et al. [28] | 117 | 2006–2015 | 2–4 w | LINAC | 15–30 Gy/1–5 fr | SRS 18.6 HSRT 33.7 | 0–3 mm | 22 |
| Jhaveri et al. [29] | 133 | 2006–2016 | 3–4 w | LINAC | 30–35/5 fr | 14.7 (1 mm) 20.3(> 1 mm) | 1 mm (25.2%) > 1 mm (74.8%) | 17.7 |
| Minniti et al. [30] | 95 | 2011–2017 | 3 w | LINAC | 27/3 fr | 22.4 (6.3–67.4) | CTV, 1 mm PTV, 1 mm | 13 |
| Navarria et al. [31] | 101 | 2015–2018 | 3–4 w | LINAC | 30/3 fr | 52.9 (7.6–282.9) | 2 mm | 26 |
| Soliman et al. [32] | 122 | 2009–2014 | 3–4 w | LINAC | 30/5 fr | 30.1 | 2 mm | 16 |
| El Shafie et al. [33] | 101 | 2015–2019 | 5.1 w | CK SRS/ HSRT (50); WBRT (51) | 30–35/5 fr | 18.2 | 2 mm | 22.8 |
| Faruqi et al. [34] | 118 | NR | 6 w | LINAC | 25–35/5 fr | 24.9 | 2 mm | 12 |
| Garimall et al. [35] | 134 | 2012–2018 | 4 w | LINAC | 24/3 fr (most frequent) | 28 (2.4–149.2) | 1–2 mm | 14 |
| Eitz et al. [36] | 558 | 2003–2019 | 5 w (4–6) | LINAC | 30/5 fr (most frequent) | 23.9 (13.5–36.3) | 2–3 mm | 12.3 |
| Shi et al. [37] | 422 | 2007–2018 | 3 w (2–4) | CK | 24–27/3 fr (85%); SRS 16–18 (15%) | 14.3 (9.1–22.2) | 1–3 mm (76%) 0 mm (24%) | 10.1 |
| References | 1-Year LC (%) | 1-Year DP (%) | 1-Year OS (%) | BED Gy10 (Tumor) | BED Gy2 (normal brain) | LMD (%) | Symptomatic RN (%) |
|---|---|---|---|---|---|---|---|
| Minniti et al. [24] | 93 | 50 | 69 | 51.3 | 148.5 | 8 | 9 (7 and 16 at 1 and 2 years) |
| Ahmed et al. [25] | 87 | 49.1 | 65.2 | 37.5–48 | 87.5–120 | 10 | 1.5 |
| Keller et al. [26] | 88.2 | 39.3 | 62.5 | 69.3 | 214.5 | 10.6% at 1 year | 15.4 at 1 year |
| Minniti et al., [27] | 88 | 45 | 58 | 51.3 | 148.5 | 9 | 15 (13 at 1 year) |
| Zhong et al. [28] | 87.7 (size ≤ 4 cm) 84 (size > 4 cm) | 46.7 (size ≤ 4 cm) 55 (size > 4 cm) | 80.6 (size ≤ 4 cm) 67.6 (size > 4 cm) | SRS 46.8 HSRT 35.7–49.2 | SRS 161.5 HSRT 87.5–147.5 | 13.1 (≤ 4 cm) 15.1 (> 4 cm) | 26.9 (≤ 4 cm) 28.4 (> 4 cm) |
| Jhaveri et al. [29] | 85 | 45 | NR ( median 15.6 months) | 48–59.5 | 120–157.5 | 12.8 | 21.1 (16.7 at 1 year) |
| Minniti et al. [30] | 88 | 50 | 59 | 51.3 | 148.5 | 7 | 12 at 1 year |
| Navarria et al. [31] | 85.9 | 32 | 81.9 | 60 | 180 | 8.9 | 25.7 (5.9 grade 3) |
| Soliman et al. [32] | 84 | 45 | 62 | 48 | 120 | 22 | 6 |
| El Shafie et al. [33] | SRS/HSRT 94.9 WBRT 81.7 | SRS/HSRT 42 WBRT 35 | SRS/HSRT 80 WBRT 50 (p < 0.002) | 48–59.5 | 120–157.5 | 8 | 6 |
| Faruqi et al. [34] | 84 | NR | 62 | 37.5–49.5 | 87.5–157.5 | NR | 7.6 |
| Garimall et al. [35] | 92 | NR | NR | 43.2 | 120 | NR | 2 |
| Eitz et al. [36] | 84 | 45 | 65 | 48 | 120 | 13.1 | 8.6 |
| Shi et al. [37] | 93.5 | 44 | 13.9 | HSRT 43.2–51.3; SRS 41.6–50.4 | HSRT 120–148.5; SRS 144–180 | 15.8 (13 at 1 year) | 9 |
LINAC, linear accelerator; GK, Gamma Knife; CK, CyberKnife; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; HSRT, hypofractionated stereotactic radiation therapy; OBS, observation; BED Gy10, biological equivalent dose with an α/β ratio of 10 Gy; BED Gy2, biological equivalent dose with an α/β ratio of 2 Gy; w, weeks; LC, local control; DP, dostant progression; OS, overall survival; NR, not reported